Serbia
Tuberculosis profile
Population  2012 9.6 million
Estimates of TB burden * 2012 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.14 (0.12–0.16) 1.5 (1.3–1.6)
Mortality (HIV+TB only) <0.01 (<0.01–<0.01) 0.01 (0.01–0.02)
Prevalence  (includes HIV+TB) 3 (1.2–5.4) 31 (13–57)
Incidence  (includes HIV+TB) 2.2 (1.9–2.4) 23 (20–26)
Incidence (HIV+TB only) <0.01 (<0.01–<0.01) 0.07 (0.06–0.08)
Case detection, all forms (%) 87 (77–100)    
TB case notifications 2012        
New cases   (%) Retreatment cases (%)
Smear-positive 819 (47) Relapse 134 (75)
Smear-negative 773 (45) Treatment after failure 4 (2)
Smear-unknown / not done 14 (<1) Treatment after default 8 (4)
Extrapulmonary 130 (7) Other 33 (18)
Other 0 (0)      
Total new 1 736   Total retreatment 179  
           
Other (history unknown) 2        
Total new and relapse 1 870   Total cases notified 1 917  
New cases Smear-positive Smear-negative/ unknown/
not done
Extrapulmonary
M:F ratio 1.4 1.5 1.2
Age < 15 5 12 3
Laboratories 2012
Smear (per 100 000 population) 0.3
Culture (per 5 million population) 15.2
Drug susceptibility testing (per 5 million population) 2.1
Is second-line drug susceptibility testing available? Yes, outside
country
Treatment success rate 2011 (%)        
New smear-positive and/or culture-positive 87   Is rifampicin used
throughout treatment for
new patients?
Yes
New smear-negative/extrapulmonary 85  
Retreatment 78  
TB/HIV 2012 Number (%)
TB patients with known HIV status 39 (2)
HIV-positive TB patients 6 (15)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 0 (0)
HIV-positive TB patients on antiretroviral therapy (ART) 6 (100)
HIV-positive people screened for TB    
HIV-positive people provided with IPT    
Estimates of MDR-TB burden 2012*   New   Retreatment
% of TB cases with MDR-TB 0.84 (0.31–1.8) 3.6 (0.75–10)
MDR-TB cases among notified pulmonary
TB cases
13 (5–29) 7 (1–18)
Reported cases of MDR-TB 2012 New Retreatment Total
Cases tested for MDR-TB 716 (84%) 83 (46%) 800
Laboratory-confirmed MDR-TB cases 6 3 9
Patients started on MDR-TB treatment     9
Financing TB control 2013
National TB programme budget (US$ millions) 17
% Funded domestically 85%
% Funded internationally 9%
% Unfunded 6%
***
(Rate per 100 000 population per year)
Mortality graph
___ Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
___ Prevalence

(Rate per 100 000 population per year)
Incidence graph
__ Notifications Incidence
___
___ Incidence (HIV+TB only)

Treatment success rate (%)
tx success graph
__ New smear-positive and/or culture-positive
__ New smear-negative/extrapulmonary __
Retreatment

(Number of patients)
CPT ART graph
__ HIV-positive TB patients
__ on CPT __ on ART

Total budget (US$ millions)
Budget funding Graph
__ Funded domestically __ Funded internationally
__ Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 * Ranges represent uncertainty intervals Generated: 2014-04-24 Data: www.who.int/tb/data